Market Spotlight: Thyroid Cancer
|出版日||ページ情報||英文 47 Pages
|注目市場の分析：甲状腺がん Market Spotlight: Thyroid Cancer|
|出版日: 2019年11月26日||ページ情報: 英文 47 Pages||
This Market Spotlight report covers the thyroid cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and five-year prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2017, there were 559,800 incident cases of thyroid cancer worldwide, and expects that number to increase to 612,600 incident cases by
2026. In the same year, there were an estimated 2.0 million five-year prevalent cases of thyroid cancer worldwide, which is expected to increase to 2.2 million cases by
2026. The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
There are only five industry-sponsored drugs in active clinical development for thyroid cancer, with three drugs in Phase II and two in Phase I.
Therapies in early-to-mid-stage development for thyroid cancer focus on targets such as RET, carcinoembryonic antigen, immune system, tumor necrosis factor-alpha, and ErbB3/HER3. These therapies are administered via the oral, intravenous, and subcutaneous routes.
The release of topline Phase II trial results for GI-6207 is the only high-impact upcoming event in the thyroid cancer space. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 41%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been 13 licensing and asset acquisition deals involving thyroid cancer drugs during 2014-19. The $1,550m exclusive global collaboration signed in November 2017 between Bayer and Loxo Oncology for the development and commercialization of two novel oncology therapies selectively targeting genetic drivers of cancer was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.
The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 33 trials.
Novartis leads industry sponsors with the highest overall number of clinical trials for thyroid cancer, followed by Pfizer.
10 Radioactive iodine (RAI) therapy
10 Thyroid hormone therapy
10 External beam radiation therapy
11 Targeted therapy
23 Selpercatinib for Thyroid Cancer (September 29, 2019)
24 BLU-667 for Thyroid Cancer (June 3, 2019)
26 BLU-667 for Thyroid Cancer (May 15, 2019)
27 Selumetinib for Thyroid Cancer (July 26, 2018)
29 Selumetinib for Thyroid Cancer (June 2, 2018)
34 Lift-Off For Lilly In Cancer Genetics With Loxo Buy
39 Sponsors by status
40 Sponsors by phase
41 Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib
42 Prescription information